Ambrx Biopharma Inc (DELISTED) (AMAM:DL)
27.99
+0.01
(+0.04%)
USD |
NASDAQ |
Mar 06, 16:00
Ambrx Biopharma Revenue (Quarterly): 0.053M for Sept. 30, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2023 | 0.053M |
June 30, 2023 | 1.123M |
March 31, 2023 | 0.024M |
December 31, 2022 | 2.893M |
Date | Value |
---|---|
September 30, 2022 | 1.597M |
June 30, 2022 | 1.299M |
March 31, 2022 | 1.613M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.024M
Minimum
Mar 2023
2.893M
Maximum
Dec 2022
1.229M
Average
1.299M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
Johnson & Johnson | 22.47B |
Axonics Inc | 116.19M |
Harpoon Therapeutics Inc (DELISTED) | 4.448M |
Merck & Co Inc | 16.66B |
RayzeBio inc (DELISTED) | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -22.99M |
Total Expenses (Quarterly) | 25.68M |
EPS Diluted (Quarterly) | -0.37 |
Enterprise Value | 1.542B |
Profit Margin (Quarterly) | -43.38K% |
Earnings Yield | -1.82% |
Normalized Earnings Yield | -1.846 |